Search

Search

这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

首页
...
研究领域生物医学和临床科学瘤学和致癌症预测和预后标志物
在细胞癌的辅助试验中基于TNM的风险资格

在细胞癌的辅助试验中基于TNM的风险资格

Jens Bedke ¹, Axel Bex ²

Jens Bedke ¹, Axel Bex ²

¹Department of Urology and Transplantation Surgery, Klinikum Stuttgart-Katharinenhospital, 70174 Stuttgart, Germany; Stuttgart Cancer Center-Tumorzentrum Eva Mayr-Stihl, Stuttgart, Germany.
²The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

⁰Department of Urology and Transplantation Surgery, Klinikum Stuttgart-Katharinenhospital, 70174 Stuttgart, Germany; Stuttgart Cancer Center-Tumorzentrum Eva Mayr-Stihl, Stuttgart, Germany.

Lancet +

|

2023年七月31日

相关实验视频

These videos have been matched automatically. Contact us if they are not relevant.

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

See all related videos

概括

No abstract available on PubMed

相关实验视频

这些视频已自动匹配 Contact us 如果它们不相关

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

See all related videos

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies